Compare Crispr Therapeutics AG (CRSP) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SoFi Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while SoFi Technologies Inc trades at $18.68 (market cap $23.79B). The key difference: SoFi Technologies Inc is far larger — about 4.8× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | SOFI | |
|---|---|---|
Market Cap | $4.97B | $23.79B |
Sector | Health | Financials |
52-Week High | $76.78 | $32.21 |
52-Week Low | $44.34 | $15.15 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SoFi trades at $18.13, down 3.46% today but up from its year-to-date low near $15. The stock is in a bullish technical trend with key support at $18 and resistance at $19. Fundamentally, revenue grew to $3.61B in 2025 with net income of $481.32M, though cash flow from operations remains negative. Recent news highlights AI acquisitions and ETF launches as growth catalysts.
The outlook is mixed: analyst consensus targets $22.43 (24% upside) with 33% buy ratings, but risks include persistent negative operating cash flow and high P/E of 40.29. Earnings beats in recent quarters support growth narrative, yet profitability sustainability and interest rate sensitivity are key investor concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
